Last reviewed · How we verify
AD109
AD109 is an adenosine A2A receptor antagonist that blocks inhibitory signaling in the tumor microenvironment to enhance immune cell activation.
AD109 is an adenosine A2A receptor antagonist that blocks inhibitory signaling in the tumor microenvironment to enhance immune cell activation. Used for Advanced or metastatic solid tumors (in combination with checkpoint inhibitors).
At a glance
| Generic name | AD109 |
|---|---|
| Sponsor | Apnimed |
| Drug class | Adenosine A2A receptor antagonist |
| Target | Adenosine A2A receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
AD109 works by antagonizing adenosine A2A receptors, which are expressed on immune cells and suppress anti-tumor immunity when activated by adenosine in the tumor microenvironment. By blocking this pathway, the drug relieves immune suppression and enhances T cell and natural killer cell function, promoting anti-tumor immune responses. This mechanism is often combined with checkpoint inhibitors to improve overall anti-tumor efficacy.
Approved indications
- Advanced or metastatic solid tumors (in combination with checkpoint inhibitors)
Common side effects
- Fatigue
- Nausea
- Diarrhea
- Headache
Key clinical trials
- Parallel Arm Trial of AD109 and Placebo With Patients With OSA (LunAIRo) (PHASE3)
- Parallel-Arm Study to Compare AD109 to Placebo With Patients With OSA (SynAIRgy Study) (PHASE3)
- Continuation Protocol for Obstructive Sleep Apnea (OSA) (PHASE3)
- Study That Tests AD109 in Patients Taking GLP-1 Drugs (PHASE2)
- Crossover Trial of AD109 in Obstructive Sleep Apnea (PHASE2)
- AD109 Dose Finding in Mild to Moderate OSA (PHASE2)
- Parallel Arm Trial of AD109 and AD504 In Patients With OSA (PHASE2)
- A Study to Compare Pharmacokinetic Parameters and Safety Profiles Between AD-109 and AD-1091 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AD109 CI brief — competitive landscape report
- AD109 updates RSS · CI watch RSS
- Apnimed portfolio CI